Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) news covers the company’s progress as a biopharmaceutical issuer focused on therapies for autoimmune diseases with high unmet medical needs. Investors and followers of AUPH can use this page to review company‑issued updates, financial announcements and clinical data disclosures that shape the outlook for its products and pipeline.
News releases from Aurinia frequently highlight commercial performance and medical data for LUPKYNIS (voclosporin), which the company describes as the first FDA‑approved oral therapy for adult patients with active lupus nephritis. Regular quarterly earnings announcements detail trends in net product sales of LUPKYNIS, license, collaboration and royalty revenue, net income and cash flows. These updates are often accompanied by guidance ranges for total revenue and net product sales, as well as information on the company’s share repurchase plan.
In addition to financial results, Aurinia’s news flow includes clinical and scientific milestones. The company has reported post‑hoc analyses from the AURORA 1 trial, real‑world data from the ENLIGHT‑LN registry and new mechanistic findings on voclosporin, often presented at major rheumatology and nephrology meetings. Separate announcements describe progress with aritinercept (AUR200), a dual BAFF and APRIL inhibitor, including Phase 1 study results and plans for further clinical development in autoimmune diseases.
Visitors to this AUPH news page can review a stream of earnings releases, pipeline updates, medical conference presentations and regulatory‑related communications drawn from company press releases and SEC‑referenced materials. This provides a centralized view of how Aurinia communicates its commercial performance, clinical findings and strategic steps in autoimmune disease drug development.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced the grant of inducement stock options and restricted stock units (RSUs) to three new employees. The inducement stock options total 89,830 shares at an exercise price of $8.99, the closing price on March 3, 2023. The RSUs granted amount to 54,850 shares. The options vest over three years, with one-third vesting after one year and the remainder vesting in equal monthly installments. The RSUs vest in three equal annual installments. This move complies with Nasdaq Listing Rule 5635(c)(4) and indicates Aurinia's commitment to attracting talent as it advances treatments for autoimmune and rare diseases.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported a significant increase in financial performance for the fourth quarter and full year 2022. Total net revenue reached $28.4 million for Q4 2022, a 21% increase from Q4 2021, and $134.0 million for the full year, reflecting a 194% growth year-over-year. The company’s cash and equivalents stood at $389.4 million at year-end. Aurinia maintains revenue guidance for 2023 at $120 to $140 million from sales of LUPKYNIS, indicating continued growth. Despite a net loss of $108.2 million for the year, the company has sufficient resources to support ongoing operations and expansion efforts.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced that CEO Peter Greenleaf will present at the Oppenheimer 33rd Annual Virtual Healthcare Conference from March 13-15, 2023. His presentation is scheduled for March 14, from 9:20 to 9:50 AM ET. Interested individuals can access the live audio webcast via the Investors section of the Aurinia website.
Aurinia is dedicated to addressing autoimmune, kidney, and rare diseases, having launched LUPKYNIS® (voclosporin) in January 2021 as the first FDA-approved oral treatment for lupus nephritis.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its financial and operational results for Q4 and full year 2023 on February 28, 2023, before market opening. A conference call/webcast is scheduled for 8:30 am ET the same day to discuss these results and offer a business update. Participants can join by dialing 877-407-9170 or accessing the audio webcast on Aurinia's website. The company, headquartered in Victoria, British Columbia, focuses on therapies for serious diseases, having launched LUPKYNIS® in January 2021, the first oral treatment approved by the FDA for active lupus nephritis.
Aurinia Pharmaceuticals announced the grant of inducement stock options and restricted stock units (RSUs) to 7 new employees. The options allow the purchase of 70,070 common shares at $9.05 each, the closing price on February 3, 2023. These inducements are in accordance with Nasdaq Listing Rule 5635(c)(4) and mark a strategic move to attract talent. The stock options have a 10-year term, vesting over three years, while the RSUs will vest in three equal annual installments. Aurinia continues to focus on therapies for diseases with high unmet medical needs, including its FDA-approved treatment for lupus nephritis.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that the Patent Trial and Appeal Board (PTAB) has terminated the Inter Partes Review (IPR) related to its U.S. Patent No. 10,286,036. This patent is associated with LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis (LN), a serious condition affecting many patients with systemic lupus erythematosus (SLE). With approximately 200,000-300,000 individuals in the U.S. diagnosed with SLE, around 50% may develop LN, emphasizing the therapeutic importance of LUPKYNIS for these patients.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the allowance of a new patent for its product LUPKYNIS by the US Patent and Trademark Office, enhancing its dosing regimen for lupus nephritis treatment. This patent, along with a similar notice from the European Patent Office, could protect LUPKYNIS until 2037, extending its market exclusivity. The patent specifics align with FDA guidelines and aim to improve patient outcomes through precise eGFR-based dosing. CEO Peter Greenleaf emphasized the importance of this intellectual property in strengthening their market position.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported preliminary unaudited net revenues of approximately
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that Peter Greenleaf, CEO, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11 at 4:30 p.m. PT in San Francisco, CA. Interested parties can listen to the live audio webcast on the Aurinia corporate website under the 'News/Events' section. Aurinia is dedicated to developing therapies for serious diseases, having launched LUPKYNIS®, the first FDA-approved oral treatment for active lupus nephritis in January 2021.
Aurinia Pharmaceuticals (NASDAQ: AUPH) and Sun Pharmaceuticals have reached a settlement regarding patent infringement claims related to Sun's CEQUA® product. The settlement includes a joint motion to dismiss an Inter Partes Review of Aurinia's U.S. Patent No. 10,286,036. This agreement is contingent on the U.S. Patent Trial and Appeal Board terminating the Inter Partes Review. Both companies will cease further claims against each other under this settlement.